Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries (U01)

Leading Research to Understand, Treat, and Prevent Infectious, Immunologic, and Allergic Diseases          Visit us on the Web The NIAID Radiation and Nuclear Countermeasures Program (RNCP) supports extramural research to develop safe and effective radiation medical countermeasures for clinical use during a radiation public health emergency. We are pleased to present the following new funding opportunity: RFA-AI-21-068: Development of Microbiome-Related Approaches for Diagnosis/Mitigation/Treatment of Radiation Injuries (U01 Clinical Trial Not Allowed) The purpose of this initiative is to advance the understanding of effects on, and the influence of, the microbiome in radiation injury. This initiative will support research to explore how the microbiome affects severity of radiation injury and how the microbiome itself is impacted by exposure to radiation and to develop medical countermeasures (MCMs) targeting the microbiome to mitigate or treat radiation injury. Other areas of interest include identification of microbiome targets for radiation drug development and discovery of microbiome signatures predictive of radiation injury or recovery. Potential outcomes include the discovery of new mechanisms of action, development of new MCMs for radiation injury, and establishment of biomarkers for radiation biodosimetry to be used in the event of a radiation public health emergency. Applications are due February 09, 2022, by 5:00 PM local time of applicant organization. Please address inquiries to the appropriate Agency Contacts listed in Section VII Agency Contacts. Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID). This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107